These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
594 related articles for article (PubMed ID: 32447027)
1. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer. Yim J; Koh J; Kim S; Song SG; Ahn HK; Kim YA; Jeon YK; Chung DH Eur J Cancer; 2020 Jul; 133():74-85. PubMed ID: 32447027 [TBL] [Abstract][Full Text] [Related]
2. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021 [TBL] [Abstract][Full Text] [Related]
3. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Mao Y; Li W; Chen K; Xie Y; Liu Q; Yao M; Duan W; Zhou X; Liang R; Tao M Oncotarget; 2015 Feb; 6(5):3452-61. PubMed ID: 25609202 [TBL] [Abstract][Full Text] [Related]
4. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer. Jin Y; Zhang P; Li J; Zhao J; Liu C; Yang F; Yang D; Gao A; Lin W; Ma X; Sun Y Int J Clin Exp Pathol; 2015; 8(11):13987-95. PubMed ID: 26823710 [TBL] [Abstract][Full Text] [Related]
5. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467 [No Abstract] [Full Text] [Related]
6. Dynamic changes in PD-L1 expression and CD8 Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259 [TBL] [Abstract][Full Text] [Related]
8. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation. MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360 [TBL] [Abstract][Full Text] [Related]
9. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer. Ahn H; Lee HJ; Lee JH; Cho HD; Oh MH; Son JW; Jang SH Pathol Res Pract; 2020 Nov; 216(11):153188. PubMed ID: 32919305 [TBL] [Abstract][Full Text] [Related]
12. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients. El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185 [TBL] [Abstract][Full Text] [Related]
13. B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Xu YH; Zhang GB; Wang JM; Hu HC Saudi Med J; 2010 Sep; 31(9):980-6. PubMed ID: 20844808 [TBL] [Abstract][Full Text] [Related]
14. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma. Lu Z; Zhao ZX; Cheng P; Huang F; Guan X; Zhang MG; Chen HP; Liu Z; Jiang Z; Zheng ZX; Zou SM; Wang XS Mod Pathol; 2020 Nov; 33(11):2330-2340. PubMed ID: 32514163 [TBL] [Abstract][Full Text] [Related]
15. B7-H3 on breast cancer cell MCF7 inhibits IFN-γ release from tumour-infiltrating T cells. Shao L; Yu Q; Xia R; Zhang J; Gu S; Yu D; Zhuang Z Pathol Res Pract; 2021 Aug; 224():153461. PubMed ID: 34265738 [TBL] [Abstract][Full Text] [Related]
17. PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. Varki V; Ioffe OB; Bentzen SM; Heath J; Cellini A; Feliciano J; Zandberg DP Cancer Immunol Immunother; 2018 May; 67(5):805-814. PubMed ID: 29484464 [TBL] [Abstract][Full Text] [Related]
18. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study. Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075 [TBL] [Abstract][Full Text] [Related]